eribulin mesylate + capecitabine
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Estrogen Receptor Positive Tumor
Conditions
Estrogen Receptor Positive Tumor, Breast Cancer
Trial Timeline
Aug 1, 2011 → May 1, 2014
NCT ID
NCT01439282About eribulin mesylate + capecitabine
eribulin mesylate + capecitabine is a phase 2 stage product being developed by Eisai for Estrogen Receptor Positive Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT01439282. Target conditions include Estrogen Receptor Positive Tumor, Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01439282 | Phase 2 | Completed |
| NCT01323530 | Phase 1/2 | Completed |
| NCT00337103 | Phase 3 | Completed |
Competing Products
20 competing products in Estrogen Receptor Positive Tumor